Susan Lee Perlman MD
Movement Disorder, Neurodegenerative, Neurodevelopmental Disabilities
Professor, Neurology, UCLA School of Medicine
Join to view full profile
300 Medical PlazaSuite B 200Los Angeles, CA 90095
Phone+1 310-794-1195
Fax+1 310-794-1195
Dr. Perlman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1976 - 1979- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1975 - 1976
Stony Brook University Health Sciences Center School of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 1976 - 2028
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- Super Doctor SuperDoctors.com
Clinical Trials
Publications & Presentations
PubMed
- Axial Function Reflects Global Severity in Inherited Ataxias: The Upright Stability Score in Ambulatory Friedreich vs. Spinocerebellar Ataxia.Christian Rummey, S H Subramony, David R Lynch, Louise A Corben, Martin B Delatycki
Annals of Clinical and Translational Neurology. 2026-11-04 - 1 citationsNeurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-bli...Sam Russo, Stefan Zielen, Barbara Pietrucha, Jordis Trischler, Susan Perlman
The Lancet. Child & Adolescent Health. 2026-10-01 - Frequency of ZFHX3-Mediated Spinocerebellar Ataxia 4 in a US Undiagnosed Ataxia Cohort.Annie Chen, Udbhav Avadhani, Kathie Ngo, Rosario I Corona, George de V Carvalho Neto
Movement Disorders. 2026-09-01
Press Mentions
Skyclarys (Omaveloxolone) Becomes the First FDA-Approved Treatment for Friedreich’s AtaxiaMarch 10th, 2023- FDA Approves SkyclarysJanuary 3rd, 2023
- Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressDecember 8th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
